9 results
- Primary study objective: To demonstrate the superiority of the ablative microboost dose schedule regarding 5-year biochemical no evidence of disease rate compared to the current standard of care.- Secondary study objectives: Establish and compare…
Objective: Primary Objective: to compare the immediate and postoperative pain (up to 6 weeks) between the Ajust® and TVT-O® proceduresSecondary Objective(s): 1. Objective cure of the SUI at 6 and 12 months follow up2. Subjective cure and improvement…
The objective of the project is to study the effect of conservative, non-surgical treatments of pelvic organ prolapse in a randomized clinical trial. The treatments under study, pessaries and pelvic floor physiotherapy, aim at reducing the symptoms…
To Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or Mildly Symptomatic
To Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients compared to placebo.
The main objective of this study is to investigate whether access to a peer support platform, age-dependent information provision and games in a smartphone application increases self-reported quality of life, for children receiving a stoma.
This study has been transitioned to CTIS with ID 2024-513521-23-00 check the CTIS register for the current data. All efficacy and safety objectives will compare enzalutamide plus leuprolide and enzalutamide monotherapyversus placebo plus leuprolide.
This study has been transitioned to CTIS with ID 2024-514991-41-01 check the CTIS register for the current data. To assess the proportion of UTUC patients with adequate renal function and fit to receive either neo- or adjuvant cisplatin-based…
To assess non-inferiority of treating patients with localized, intermediate risk prostate cancer in two fractions of 12 Gray (Gy) with a boost to the gross tumor volume of 13.5 Gy per fraction in 8 days, as compared to standard care (36.25 Gy in…